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Cbu Cl estimated in elderly patients was 43.55% with respect to 
younger patients. Besides, the Cbu Cl estimated was 5.69 % higher and 
26.85 % lower than the Cbu Cl calculated using the Calvert equation 
for young and elderly patients groups respectively.
Conclusions: The Cbu Cl calculation by means of Calvert formula 
showed under-estimation of the dose to administer at younger patients 
and upper-estimation of the dose to elderly patients. It is necessary to 
study the covariates which contribute to take away the strength of the 
Calvert equation, because affect the efﬁcacy and toxicity of Carbopla-
tin. 
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Background: The clinical beneﬁt of non-cisplatin doublets vs a single 
agent in elderly or unﬁt p is still controversial. The present study 
focuses on clinical outcome with VRL/GEM in elderly p and the role 
of functional status and comorbidities. Genetic predictive markers of 
response to VRL/GEM will also be examined in genomic and cDNA 
from tumor and circulating tumor DNA.
Methods: 145 chemonaive p with stage IIIB (pleural effusion or 
supraclavicular lymph nodes)-IV or recurrent NSCLC and age > 70 
years were accrued at 32 sites between April 2004 and January 2006. 
Treatment consisted of VRL 25 mg/m2 IV or 60-80 mg/m2 oral plus 
GEM 1200 mg/m2, days 1, 8 every 21 days. Activities of daily living 
(ADL), instrumental activities of daily living (IADL) and comorbidi-
ties were evaluated. DNA samples were collected from primary tumors 
for the assessment of microtubule associated protein 4 (MAP4) and 
from serum for the checkpoint with forkhead-associated and ring ﬁnger 
(CHFR) methylation.
Results: Data on 130 p is available for toxicity and 95 for response. 
Median age 76 years (69-83); males: 86.8%; smokers: 70.5%; PS 0-1: 
83.9%; adenocarcinoma: 34.4% / squamous: 48%; stage IIIB: 22.7%, 
IV: 77.3%. Self-sufﬁciency in ADL and IADL was 77.4% and 45.2% 
of the p analyzed. 68% of the p had comorbidities. Median cycles: 3 
(1-8). 461 cycles were performed, 16.3% were delayed and 2.1% had 
dose reduction. Hematological toxicities (%p): grade 3/4 neutropenia, 
7.8%/4.7%; grade 3/4 thrombocytopenia, 2.3%/0.8%; grade 3 anemia, 
3.1%. Efﬁcacy in evaluable population: PR, 23.2% (95% CI, 15.1% to 
32.9%); SD, 41.1%. 24 p died during the treatment period (non toxicity 
related) and 21 p were not evaluable. With a median follow up of 5.8 
months, median survival for the whole population was 4.97 months 
(m), progression free survival 4.53 m, event free survival 3.43 m, 1-
year survival 26.6%. Statistically signiﬁcant differences in median sur-
vival were observed among subgroups: PS 0-1/2, 6.5/2.3 m (p<0.001); 
sex male/female, 4.5/9.7 m (p 0.027); ADL <6/=6, 3.4/7.1 m (p 0.023).
Conclusions: This trial conﬁrms that VRL/GEM is effective, present-
ing a favourable response/toxicity ratio in elderly p with advanced 
NSCLC. Complete data on genetic markers will be presented. 
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Metronomic chemotherapy in pre-treated patients with advanced 
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Background: Recent experimental studies have suggested that chronic 
administration of comparatively low doses of cytotoxic drugs at close, 
regular intervals, with no prolonged drug-free interruptions, known as 
“metronomic chemotherapy”, may target tumor-associated endothelial 
cells and can induce clinical meaningful effect in selected patients with 
solid tumors. 
Purpose: We report initial results of compassionate use of metronomic 
cyclophosphamide (50 mg p.o. daily until clinical disease progres-
sion or any grade 3-4 toxicity) in patients with advanced or metastatic 
lung cancer pre-treated with at least one platinum-based regimen and 
deemed unﬁt to further cytotoxic therapy.
Results: Data on sixteen patients enrolled between January 2005 and 
June 2006 are evaluable: most had a Karnofsky performance status of 
70% (10 pts), metastatic disease (9 pts), and 14 were pre-treated with 
a cisplatin/vinorelbine regimen; 15 had progressive disease at study 
entry, and 9 had progressive disease during the last therapy. One patient 
interrupted treatment due to recurrent grade-2 bladder hemorrhage. We 
noticed 2 partial remission (PR) (12%, 95% CI 0-28%) and 9 stable 
disease (SD) (56%, 95% CI 32-80%); the clinical beneﬁt rate (PR 
plus SD for > or = 24 weeks) in all pts were 44% (95% CI, 19-68%). 
Median survival was 11.9 months (95% CI 2.3-21.5 mo.) and 1-year 
survival rate was 47.7%. 
Conclusion: Metronomic cyclophosphamide chemotherapy is effective 
and minimally toxic in pre-treated lung cancer patients. 
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Background: Along with an acceptable tolerability proﬁle, single 
agent oral vinorelbine has shown to be effective in elderly NSCLC 
p. The oral formulation avoids the side effects associated with the IV 
injection, may reduce administration and toxicity-related costs and is 
easy to administer. Due to these advantages, single agent oral vinorel-
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bine treatment could be considered as an optimal option for these p. We 
retrospectively evaluated efﬁcacy and toxicity of oral vinorelbine ad-
ministered as single agent for ﬁrst-line NSCLC treatment in elderly p. 
Methods: 1 cycle was equivalent to a 3-week period. Treatment 
consisted of oral vinorelbine 60 mg/m2/week during the ﬁrst 3 weeks, 
escalating to 80 mg/m2/week if no grade 4 or no more than two grade 3 
neutropenia were observed during ﬁrst cycle. At 80 mg/m2, if grade 4 
or 2 consecutive grade 3 neutropenia ocurred, the dose was reduced to 
60 mg/m2. Treatment was administered for 6 cycles, unless progression 
of the disease was observed earlier.
Results: Data on 46 p were collected in 11 Spanish centres. Median 
age was 77 years (range 70-85). Male, 87%; female, 13%. ECOG PS 0, 
26.8%; 1, 68.3%; 2, 4.9%. Stage IIIA, 4.3%; IIIB, 30.4%; IV, 65.2%. 
Histology: scamous, 56.5%; adenocarcinoma, 28.3%. Self-sufﬁciency 
in ADL and IADL was 82.5% and 55% of the p analyzed. 81.9% of the 
p had comorbidities. 46 p are available for toxicity and 27 for response. 
Median cycles: 3 (1-8). 158 cycles were performed, 13.4% were 
delayed and 5.4% had dose reduction. Hematological toxicities (%p): 
grade 3/4 neutropenia, 8.7%/8.7%. Grade 3 non-hematological toxici-
ties: asthenia, 6.5%; anorexia, 4.3%; respiratory, 4.3%; pain, 4.3%; 
nausea and vomiting, 2.2%. No grade 4 non-hematological toxicities 
were reported. In the evaluable p, 3 PR (11.1%) and 11 SD (40.7%) 
were reported (disease control 51.8%). With a median follow-up of 
3.4 months (m), median survival for the whole population was 6.37 m, 
progression free survival 3 m. 
Conclusions: This trial conﬁrms the results of previous studies with 
single agent oral vinorelbine in elderly NSCLC p. It has been shown 
that this treatment offers a reasonable control of disease, with easy ad-
ministration and a favorable toxicity proﬁle for this speciﬁc population.
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Background and Objective: How to improve the postoperative 5-year 
survival rate for lung cancer and to give more patients a chance of 
surgery have become research hot spots. The aim of this research is 
to evaluate the clinical and pathohistological responses and effects of 
preoperative bronchial artery infusion (BAI) chemotherapy in patients 
with locally advanced (stage III) non-small cell lung cancer (NSCLC). 
Methods: A total of 92 cases with locally advanced NSCLC were ran-
domly divided into two groups. BAI group received BAI chemotherapy 
for 2 cycles before surgical resection. Surgery group received operation 
only. The complete resection rate and clinical response were compared 
between the two groups. 
Results: In the BAI group, the clinical response rate and the patho-
histological response rate were 68.3% and 51.3% respectively. The 
complete resection rate in the BAI was 89.7%, which was signiﬁcantly 
higher than that in the surgery group (72.5% )(P<0.05). The 1- and 2-
year survival rates were 100% and 74.4% in the BAI group, and 94.1% 
and 60.0% in the surgery group.
Conclusion: BAI neoadjuvant chemotherapy is safe and effective, 
which has a good clinical and pathohistological response. It might 
increase the complete resection rate of the tumor of the tumor and 
improve the long-term survial rate of stage III NSCLC patients.
This work was supported by grants from Foundation of Science and 
Technology Department of Da Lian. (to LI Mingwu)
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Background: We previously reported the outcomes of ATP-CRA-
guided platinum-based 2-drug chemotherapy for unresectable NSCLC 
(CANCER, in press). The study showed more favorable response and 
survival in chemo-sensitive subgroup than in chemo-resistant subgroup 
within assay-guided chemotherapy group. We retrospectively compared 
outcomes of assay-guided chemotherapy and empirical chemotherapy 
in this study.
Methods: From Sep. 2003 to Oct. 2005, we performed an in vitro 
chemosensitivity test, ATP-CRA. According to the assay results, plati-
num-based 2-drug chemotherapy was given to patients with chemo-
naïve, unresectable NSCLC. At the same period, medical records of 
unresectable NSCLC patients receiving platinum-based empirical 
chemotherapy were reviewed retropectively. Prognostic variables such 
as performance status (PS), stage, and chemotherapy regimen were 
matched with the ratio of 1: 3-4. Chemotherapy response and progrers-
sion-free survival (PFS) were compared between the assay-guided and 
empirical chemotherapy groups. 
Results: Eighty-two patients were enrolled. Eighteen were included 
in assay-guided group (AG) and 64 in empirical group (EG). Seventy 
(85.4%) patients had Eastern Cooperative Oncology Group (ECOG) 
PS of 0-1 and 12 (14.6%) had ECOG PS of 2. Stage IIIB was in 24 
(29.3%) patients and stage IV in 58 (70.7%). Fifty (61.0%) patients 
received paclitaxel plus platinum and 32 (39.0%) received gemcitabine 
plus platinum. These 3 prognosticators were well matched in the 
determined ratio. Other variables such as age, sex, brain metastasis, and 
histology were not also signiﬁcantly different between the 2 groups. 
The median cycles of admistered chemotherapy were 3 in AG and 4 
in EG. (P=0.267). AG showed a trend for higher response rate (50.0% 
vs 37.5% in EG; P=0.339). However, the median PFS was not dif-
ferent between the 2 groups (4.4 months in AG vs 4.4 months in EG; 
P=0.624).
Conclusions: Clinical outcomes of ATP-CRA-guided platinum-based 
chemotherapy and empirical chemotherapy were not different in 
chemo-naïve, unsesectable NSCLC.
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